AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – What’s Next?

AstraZeneca PLC (LON:AZN)’s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02. AstraZeneca shares last traded at £139.96, with a volume of 40,274,711 shares changing hands.

Key Headlines Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: AstraZeneca reported third-quarter revenue of approximately $16.21 billion, up 7% year over year, while earnings per share more than doubled Wall Street’s estimate. The company reaffirmed its fiscal 2026 revenue and core EPS outlook at constant exchange rates, reducing concerns about near-term execution. AstraZeneca Q3 2026 Earnings AstraZeneca Q3 Profit and Guidance
• Positive Sentiment: Pipeline potential remains significant: AstraZeneca’s CEO said upcoming drug trial readouts in 2027 could represent more than $20 billion in potential value, supporting the long-term growth narrative and helping justify the stock’s valuation. AstraZeneca 2027 Trial Readouts
• Positive Sentiment: Cost savings will fund innovation: The company launched a $1.5 billion savings program, with the goal of redirecting resources toward its drug-development pipeline. This could improve operating leverage and support future launches. AstraZeneca Savings Drive
• Positive Sentiment: Analyst confidence strengthened: Jefferies reaffirmed its “buy” rating and set a £175 price target, implying further upside based on its assessment of AstraZeneca’s earnings and pipeline prospects.
• Positive Sentiment: Promising lung-cancer data: A Tagrisso combination achieved a significant survival benefit in a lung-cancer trial, reinforcing the commercial prospects of one of AstraZeneca’s key oncology franchises. Tagrisso Lung Cancer Trial
• Negative Sentiment: Generic competition remains a headwind: AstraZeneca indicated that the loss of exclusivity for Farxiga is weighing on results, although stronger oncology sales are currently more than offsetting the impact. AstraZeneca Cancer Drugs and Farxiga

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and set a £175 target price on shares of AstraZeneca in a research report on Friday. Berenberg Bank reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, October 7th. Citigroup upped their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Royal Bank Of Canada initiated coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating and a £145 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research report on Tuesday, September 29th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of £153.57.

AstraZeneca Trading Up 7.2%

The firm has a market cap of £217.06 billion, a P/E ratio of 20.95, a P/E/G ratio of 0.86 and a beta of 0.21. The stock has a 50 day simple moving average of £123.07 and a 200-day simple moving average of £134.30. The company has a current ratio of 1.01, a quick ratio of 0.59 and a debt-to-equity ratio of 66.10.

Insider Buying and Selling

In related news, insider Michel Demare purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average price of £121.21 per share, for a total transaction of £303,025. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.